Paxmedica completes hat-301 registrational trial for pax-101

Hat-301 is the pivotal efficacy study to support upcoming nda filing top line results planned for release in july 2023 tarrytown, ny, june 01, 2023 (globe newswire) -- via newmediawire – paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (apt) for the treatment of autism spectrum disorder (asd), and other serious conditions with intractable neurologic symptoms, today announced that the eligibility review and final enrollment for the company's real world evidence study (hat-301) has been completed. patient eligibility was assessed for inclusion by an independent study adjudication committee which included a total of three subject matter expert medical reviewers.
PXMD Ratings Summary
PXMD Quant Ranking